



USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 18093/1130		Serial No. 09/668,196	
				Applicant(s): Russell, et al.			
				Filing Date: September 22, 2000		Group: Not Yet Assigned ¹⁶⁴²	
U.S. PATENT DOCUMENTS							
Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
bfo	1	5,713,858	Feb. 3, 1998	Heruth, et al.	604	93	
	2	5,980,508	Nov. 9, 1999	Cardamone, et al.	604	890.1	
	3	5,001,692	Mar. 19, 1991	Farla, et al.	369	48	
	4	4,500,512	Feb. 19, 1985	Barme	424	89	
	5	4,985,244	Jan. 15, 1991	Makino, et al.	424	89	
	6	5,137,727	Aug. 11, 1992	Eckenhoff	424	422	
	7	6,012,034	Jan. 4, 2000	Hamparian, et al.	705	2	
	8	6,026,316	Feb. 15, 2000	Kucharczyk, et al.	600	420	
	9	6,083,751	Jul. 4, 2000	Feldhaus, et al.	435	372.3	
v	10	6,095,976	Aug. 1, 2000	Nachatomy, et al.	600	443	
FOREIGN PATENT DOCUMENTS							
Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
bfo	11	Attenuvax®, Merck & Co., Inc., West Point, PA 19466, USA, September 8, 2000.					
	12	Schattner, A., Rager-Zisman, B., Bloom, B.R., (1985). Persistent Viral Infection Affects Tumorigenicity of a Neuroblastoma Cell Line, Cellular Immunology 98, 103-114.					
	13	World Health Organization, Requirements for measles, mumps and rubella vaccines and combined vaccine (live), (1994), WHO Technical Report Series, No. 840, page 102-120.					
v	14	Mitus, Anna, et al., Attenuated Measles Vaccine in Children with Acute Leukemia, (1962), American Journal of Diseases of Children, Vol. 103m page 243-246.					
EXAMINER <i>Freunda Kuntack</i>				DATE CONSIDERED 11-5-01			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.							



USPTO Form 1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

18093/1130

Serial No.

09/668,196

INFORMATION DISCLOSURE STATEMENT

Applicant(s): Russell, et al.

Filing Date: September 22, 2000

Group: ¹⁶⁴²Not Yet Assigned

66	15	Kuzumaki, Noboru, Kobayashi, Hiroshi, (1978), Reduced Transplantability of Syngenic Mouse Tumors Superinfected with Membrane Viruses in NU/NU Mice, Transplantation Copyright by The Williams & Wilkins Co., Vol. 22, No. 6.
	16	Reichard, Kirk W., et al., (1992) Newcastle Disease Virus Selectively Kills Human Tumor Cells, Journal of Surgical Research 52, 448-453.
	17	Kim, David H., (2000), Replication-Selective Microbiological agents: fighting cancer with targeted germ warfare, The Journal of Clinical Investigation, Volume 105, Number 7.
	18	Hoegen, Paul Von, Weber, Ernst, Schirmacher, Volker, (1988), Modification of Tumor cells by a low dose of Newcastle Disease Virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response, Eur. J. Immunol. 18; 1159-1166.
	19	Bateman, Andrew, et al., (2000), Fusogenic Membrane Glycoproteins As a Novel Class of Genes for the Local and Immune-mediated Control of Tumor Growth, Cancer Research 60, 1493-1497.
	20	Schirmacher, V., et al., (1999), Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus, Gene Therapy 6, 63-73.
	21	Schirmacher, V., et al. (1998), Immunization With Virus-Modified Tumor Cells,
	22	Sinkovics, Joseph G., Horvath, Joseph C., (2000), Newcastle disease virus (NDV): brief history of its oncolytic strains, Journal of Clinical Virology 14 1-15.
	23	Albonico, H.U., Braker, H.U., Husler, J., (1998), Febrile infectious childhood diseases in the history of cancer patients and matched controls, Medical Hypotheses 51, 315-320.
V	24	Von Hoegen, Paul, Weber, Ernst, Schirmacher, Volker (1988), Modification of tumor cells by a low does of Newcastle Disease Virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response, Eur. J. Immunol. 18: 1159-1166.

EXAMINER


Grenda Lounback

DATE CONSIDERED

11-5-01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.



8

Express Mail No.: EL592000348US

Date of Deposit: January 3, 2001

Page 1 of 1

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 18093/1130		Serial No. 09/668,196		
				Applicant(s): Russell, et al.				
				Filing Date: September 22, 2000		Group: Not Yet Assigned ¹⁶⁴²		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
<i>648</i>	1	Paillard, "Bystander Effects in Enzyme/Prodrug Gene Therapy", (October 10, 1997), <u>Human Gene Therapy</u> 8:1733-1736.						
	2	Bluming & Ziegler, "Regression of Burkitt's Lymphoma in Association with Measles Infection", (July 10, 1971), <u>The Lancet</u> 105-106.						
	3	Asada, "Treatment of Human Cancer with Mumps Virus", (1974), <u>Cancer</u> 34:1907-1928.						
	4	Robbins & Rapp, "Inhibition of Measles Virus Replication by Cyclic AMP", (1980), <u>Virology</u> 106: 317-326.						
	5	Robbins, "Stimulation of Measles Virus Replication by Cyclic Guanosine Monophosphate", (1991), <u>Intervirology</u> 32:204-208.						
	6	Reichard, et al., "Newcastle Disease Virus Selectively Kills Human Tumor Cells", (1992), <u>Journal of Surgical Research</u> 52:448-453.						
<i>↓</i>	7	Taqi et al., "Regression of Hodgkin's Disease After Measels", (May 16, 1981), <u>The Lancet</u> 1112						
EXAMINER <i>Freuda Laumbach</i>					DATE CONSIDERED <i>11-5-01</i>			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.</small>								